Glioblastoma market will expand fivefold to $3.3 billion by 2024; Report

14 January 2016

The glioblastoma treatment market will increase fivefold from $659 million in 2014 to $3.3 billion by 2024, representing a rapid compound annual growth rate (CAGR) of 17.4%.

According to research and consulting firm GlobalData’s latest report, this meteoric rise, which will occur across the seven Major Markets (7MM) of the USA, Spain, France, the UK, Italy, Germany and Japan, will primarily be due to the launch of new therapies for glioblastoma patients with high unmet needs.

Maxime Bourgognon, GlobalData’s analyst covering oncology and hematology, says: “Adults with glioblastoma have some of the highest levels of unmet need of any cancer patients. Despite progress having been made in treating the disease, survival rates remain low.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK